ELGAN Pharma is a late-stage neonatology-focused biotech company, dedicated to developing therapies for preterm infants.
Our therapies are safe and non-invasive, addressing high unmet medical needs for which there are no approved solutions to date.
Premature birth is the number one cause of newborn deaths worldwide. Every year, 15 million babies are born premature worldwide. More than one million of these babies die.
While not all premature babies experience complications, being born too early can cause short- and long-term health problems. Generally, the earlier a baby is born, the higher the risk of complications.
ELGN-GI demonstrated a significant improvement in gastrointestinal (GI) maturation and function, leading to faster nutritional independence while greatly reducing complications.
Address newborns’ medical challenges in the critical period post-birth
ELGN-EYE is aimed at preventing vision impairment due to retinopathy of prematurity (ROP) by stimulating normal retinal development while reducing inflammation and oxidative stress.
